PL358306A1 - Związki o aktywności agonistycznej 5-HT1A użyteczne w leczeniu zaburzeń zewnętrznej siatkówki - Google Patents

Związki o aktywności agonistycznej 5-HT1A użyteczne w leczeniu zaburzeń zewnętrznej siatkówki

Info

Publication number
PL358306A1
PL358306A1 PL01358306A PL35830601A PL358306A1 PL 358306 A1 PL358306 A1 PL 358306A1 PL 01358306 A PL01358306 A PL 01358306A PL 35830601 A PL35830601 A PL 35830601A PL 358306 A1 PL358306 A1 PL 358306A1
Authority
PL
Poland
Prior art keywords
compounds
treating disorders
activity useful
outer retina
ht1a activity
Prior art date
Application number
PL01358306A
Other languages
English (en)
Other versions
PL203709B1 (pl
Inventor
Robert J.Jr. Collier
Michael A. Kapin
Mark R. Hellberg
Thomas R. Dean
Original Assignee
Alcon Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc. filed Critical Alcon Inc.
Publication of PL358306A1 publication Critical patent/PL358306A1/pl
Publication of PL203709B1 publication Critical patent/PL203709B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
PL358306A 2000-03-17 2001-02-23 Zastosowanie związków o aktywności agonisty 5-HT1A w leczeniu zaburzeń zewnętrznej siatkówki PL203709B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
PCT/US2001/005700 WO2001070222A2 (en) 2000-03-17 2001-02-23 Compounds with 5-ht1a activity useful for treating disorders of the outer retina

Publications (2)

Publication Number Publication Date
PL358306A1 true PL358306A1 (pl) 2004-08-09
PL203709B1 PL203709B1 (pl) 2009-11-30

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
PL358306A PL203709B1 (pl) 2000-03-17 2001-02-23 Zastosowanie związków o aktywności agonisty 5-HT1A w leczeniu zaburzeń zewnętrznej siatkówki

Country Status (18)

Country Link
EP (3) EP1263434A1 (pl)
JP (5) JP2003527423A (pl)
KR (3) KR20030016239A (pl)
CN (2) CN1198605C (pl)
AR (1) AR028258A1 (pl)
AT (1) ATE247507T1 (pl)
AU (5) AU2001238552A1 (pl)
BR (3) BR0109193A (pl)
CA (3) CA2400637A1 (pl)
DE (1) DE60100625T2 (pl)
DK (1) DK1263504T3 (pl)
ES (1) ES2204848T3 (pl)
MX (3) MXPA02009071A (pl)
PL (1) PL203709B1 (pl)
PT (1) PT1263504E (pl)
TW (1) TWI268777B (pl)
WO (3) WO2001070223A1 (pl)
ZA (1) ZA200206350B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
CA2506204A1 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
EP4452267B1 (en) * 2021-12-23 2025-04-23 Cilcare Dev 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (pl) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
AU4249297A (en) * 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..

Also Published As

Publication number Publication date
CN1418121A (zh) 2003-05-14
CA2400639A1 (en) 2001-09-27
CA2400639C (en) 2011-08-16
EP1267878A2 (en) 2003-01-02
MXPA02009073A (es) 2003-03-12
ATE247507T1 (de) 2003-09-15
MXPA02009072A (es) 2003-03-12
JP4789231B2 (ja) 2011-10-12
JP2011153158A (ja) 2011-08-11
DK1263504T3 (da) 2003-12-08
JP2011037901A (ja) 2011-02-24
JP2003527423A (ja) 2003-09-16
WO2001070222A2 (en) 2001-09-27
MXPA02009071A (es) 2003-05-23
ES2204848T3 (es) 2004-05-01
KR20020082885A (ko) 2002-10-31
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
EP1263434A1 (en) 2002-12-11
PL203709B1 (pl) 2009-11-30
BR0109230A (pt) 2003-06-03
WO2001070223A1 (en) 2001-09-27
WO2001070230A3 (en) 2002-04-25
AR028258A1 (es) 2003-04-30
HK1051504A1 (en) 2003-08-08
JP2003527427A (ja) 2003-09-16
CA2400637A1 (en) 2001-09-27
AU2001239836A1 (en) 2001-10-03
DE60100625T2 (de) 2004-02-26
DE60100625D1 (de) 2003-09-25
WO2001070230A2 (en) 2001-09-27
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
ZA200206350B (en) 2003-08-08
EP1263504A2 (en) 2002-12-11
WO2001070222A3 (en) 2002-07-25
JP2003527422A (ja) 2003-09-16
KR100749191B1 (ko) 2007-08-13
KR20030009390A (ko) 2003-01-29
PT1263504E (pt) 2003-12-31
CN1198605C (zh) 2005-04-27
KR20030016239A (ko) 2003-02-26
AU2005202600B2 (en) 2008-07-31
CA2399985A1 (en) 2001-09-27
CN1418100A (zh) 2003-05-14
EP1263504B1 (en) 2003-08-20
BR0109193A (pt) 2003-05-27
AU4531001A (en) 2001-10-03
TWI268777B (en) 2006-12-21

Similar Documents

Publication Publication Date Title
PL358306A1 (pl) Związki o aktywności agonistycznej 5-HT1A użyteczne w leczeniu zaburzeń zewnętrznej siatkówki
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
AU4256801A (en) Treatment of movement disorders
PL367311A1 (pl) Podstawione ugrupowaniami chinuklidyny wielopierścieniowe związki heteroarylowe do leczenia chorób
AU2003286567A8 (en) Methods for the treatment of skin disorders
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
AU6910600A (en) Methods for the treatment of mental disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
PL368556A1 (pl) Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2
HUP0201791A3 (en) The use of escitalopram for treatment of neurotic disorders
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU7106300A (en) Treatment of skin disorders
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
EP1455780A4 (en) NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20140223